Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process (https://ibn.fm/VIL67).
The platform, called PredictBBB.ai(TM), is a next-gen AI tool that was designed to help determine whether a drug candidate is able to cross the blood-brain barrier. This is a common bottleneck in drug development, and Lantern Pharma’s platform offers 94% accuracy in predicting whether or not different compounds are able to permeate the blood-brain barrier.
With the help of this cutting-edge platform, Hoth Therapeutics can use AI-powered insights to lessen uncertainty, reduce risk, boost precision, speed up timelines, and improve candidate selection.
The PredictBBB.ai tool is a part of a larger platform being developed by Lantern Pharma, called RADR®, which stands for Response Algorithm for Drug Positioning & Rescue. The platform is used to predict the responses patients may have to different drugs, and also to help in the process of developing target compounds to fight against cancer.
Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the partnership, and what it means for cancer patients.
Lantern Pharma CEO Panna Sharma said “At Lantern Pharma, we’re very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its 94% accuracy in predicting blood-brain barrier permeability, is empowering researchers to make faster, smarter decisions, accelerating the path to life-changing therapies for patients worldwide.”
Echoing this excitement, Hoth Therapeutics CEO Robb Knie added that “Our integration of Lantern’s PredictBBB.ai tool aligns with our mission to deliver life-changing therapies while driving efficiency, reducing costs, and unlocking new opportunities for patients and shareholders alike.”
About Lantern Pharma Inc. (NASDAQ: LTRN)
Lantern Pharma Inc. is an oncology-focused, clinical stage pharma that’s concentrating on artificial intelligence, genomics, and machine learning. Applying and expanding cutting-edge AI technology, the company has the mission of delivering precision oncology therapies with reduced costs and timelines.
For more information, visit the company’s website at www.LanternPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
A study conducted recently in Ohio has found that wastewater can be a vital provider…
UC San Francisco-based scientists have developed a new immunotherapy that was successful in wiping out…
Immunotherapy has transformed cancer treatment, but the approach still faces challenges like lengthy preparation time…
The palpable euphoria surrounding the election of Democratic healthcare professionals to key positions in the…
When a person develops a serious dental infection, the pain can be excruciating, particularly when…
Disseminated on behalf of Adaptogenics Health Corp.and may include paid advertising. The federal government is…